Lixte in the News and Media:
Lixte Biotechnology Announces Initiation of a Materials Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke
December 10, 2013
Click here to read article
New anticancer compounds
could boost effectiveness of standard therapies
Lixte is developing new drug candidates that could safely bolster the effectiveness of chemotherapy and radiation and treat several diseases.
November 2013: "Biopharma Dealmakers",
Nature Biotechnology, pg. 14-15
Click here to download PDF
Lixte Biotechnology Holdings, Inc. (Lixte)
is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation.
The phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. The lead compound LB-100 is in Phase I trial and has the potential to be first-in-class.
The deacetylase inhibitors have anti-cancer activity and in model systems correct enzymes deficiencies underlying several inborn metabolic diseases including Gaucher and von Hippel-Lindau disease and neurofibromatosis type 2.
Lixte's cancer drug development strategy has led to the discovery of novel compounds with the potential to be therapeutically useful against several other important but seemingly disparate diseases. The phosphatase inhibitors are in pre-clinical development for reducing the extent of tissue damage following stroke, heart attack, and septic shock; and, the deacetylase inhibitors for prevention and treatment of neurodegenerative diseases, traumatic brain injury, and topically for fungal dermatitis
(see Product Development).